Chronic Cough Market- Global Industry Analysis and Forecast 2029

Chronic Cough Market Size by Drug Class, Diagnosis, Route of Administration, End-Users, Distribution Channel, Region – Revenue Pool Analysis, Margin Structure Assessment, Capital Flow Trends, Competitive Benchmarking & Forecast to 2029

8.2%

CAGR (2023-2029)

6.59 USD Bn.

Market Size

323

Report Pages

128

Market Tables

Overview

Global Chronic Cough Market size was valued at USD 6.59 Bn in 2022 and is expected to reach USD 11.44 Bn by 2029, at a CAGR of 8.2 %.

Chronic Cough Market Overview

A chronic cough is a persistent cough that lasts for at least eight weeks and is usually much longer. The common causes of chronic cough such as asthma, postnasal drip and acid reflux due to gastroesophageal reflux disease (GERD). It is also caused by smoking tobacco by breathing secondhand tobacco smoke over a long period of time. Chronic cough has a high global health burden, affecting about 10 percent of general adult populations. Chronic cough has a substantial impact on quality of life and thus it is a significant health issue. The report includes historical data, present and future trends, competitive environment of the Chronic Cough industry. The bottom-up approach was used to estimate the Chronic Cough market size. The market revenue is determined by the primary and secondary data collection methods. For a deeper knowledge of Chronic Cough market penetration, competitive structure, pricing and demand analysis are included in the report. The market report focuses on the drivers, challenges and major restraints of the Chronic Cough industry. The report contains a comprehensive analysis of the global Chronic Cough market's trends, forecasts, and monetary values.To know about the Research Methodology :- Request Free Sample Report

Chronic Cough Market Dynamics

Increasing prevalence of Chronic Cough to boost the market growth.
Chronic Cough is commonly caused due to smoking, chronic obstructive pulmonary disease (COPD) and chest radiographic abnormalities. Smoking is a significant cause of Chronic Cough. Over 40 percent of the participants who smoked daily and 27 percent who smoked occasionally experiences the production of phlegm and chronic cough. The prevalence of chronic cough is related to smokers. Smoking is the cause of 5-40 percent of chronic bronchitis and in the general population, chronic cough is the most common disease. The people who suffer from Chronic Cough are older, smokers and male-predominant. Hyperlipidemia, COPD, hypertension, diabetes, history of tuberculosis, cardiac disorders and stroke are also associated with chronic cough. The more prevalent causes of Chronic Cough are postnasal drip, asthma and acid reflux. For example, postnasal drip is caused due to the secretions produced in the nose dripping. These secretions include microbes and bacterial components which affect the throat and trigger a cough. This has been mainly occurring in people who grow rhinitis, allergies, colds and sinusitis. The increasing respiratory tract infection and bacterial tracheobronchitis also lead to increased incidences of Chronic Cough. All these factors contribute to the growth of the Chronic Cough market.

The growing advancements in the treatment of Chronic Cough and increasing preference for Nonpharmacologic therapies to fuel the market growth

The development of the “anatomic diagnostic protocol” is the systematic evaluation of the causes which are based on the anatomical distribution of the vagal afferent sensory nerves that regulate the cough. This improves the management of patients undergoing chronic disease. By using the anatomic diagnostic protocol, the cause of the chronic cough has been determined 88 % to 100%. Gastroesophageal reflux disease (GERD) is the most common cause of Chronic Cough and the most specific and sensitive test is 24-hour esophageal pH monitoring. This test evaluates the frequency as well as the duration of the reflux episodes and also determines the temporal relationship between the reflux events of the cough. Recently, non-pharmacological cough control therapy and pathology therapy is the more prominent treatment option for patients with chronic refractory cough. Nonpharmacologic therapies improve the health of individuals without interfering with the use of any medicine or drugs. For example companionship, exercise, massage therapy, medication and pastoral counseling. More people are precisely using non-pharmacologic therapies due to people experiencing alcohol and use drug disorders, suicidal ideation, self-inflicted injuries, and accidental or poisonings intentional drugs. As a result, rising advancements in Chronic Cough treatment and increasing preference for Nonpharmacologic therapies to fuel the growth of the

Chronic Cough Market Restraints

High Cost of Drugs and Treatments
The high costs of the drugs associated with chronic cough are due to an increase in the number of incidences of chronic cough. The unnecessary repeated testing and multiple referrals to polypharmacy and development of the comorbidities due to the deficiency of the proper treatment. The diagnosis treatments for chronic cough are very costly. The annual medical cost per patient with chronic cough including prescription medications, office visits and hospitalization is an average of USD 3266.

Lack of skilled Professionals
Sometimes the chronic cough has been complicated and the professionals cannot handle the patients and do not understand the cause of the chronic cough. This results in a negative effect on the patient’s health. Thus, the Lack of skilled and trained professionals hamper the growth of the market.

Chronic Cough Market Segment Analysis

On the basis of the drug class, the market is divided into Antihistamines, Corticosteroids, Decongestants, Combination Drugs, Antibiotics, Acid Blockers and Others. The Antihistamines segment dominated the market in 2022 with the largest market share and is expected to continue its dominance over the forecast period. Diphenhydramine is an antihistamine that is used to relieve the symptoms of hay fever, allergies and the common cold. It is a more effective drug used to prevent and treat nausea, vomiting and dizziness. This drug works by blocking certain natural substances that the human body makes while allergic reactions. Antihistamines show Broncho dilatory effects, exercise, and effects on allergen and adenosine-monophosphate-challenge testing. It is also used to prevent allergen-induced nonspecific airway hyperresponsiveness. It also plays a major role to reduce the risk of pollen allergy triggering asthma.Based on the diagnosis, the market is categorized into End bronchial Valve (EBV) Therapy, Bronchoscopy, Chest Radiography CT scan, Echocardiogram (Echo), and Others. In 2022, End Bronchial Valve (EBV) Therapy held the market with largest revenue. End Bronchial Valve (EBV) Therapy is a removable therapy, the one-way valve that reduces lung hyperinflation by permitting the trapped air to escape. EBV therapy experiences a faster recovery and returns to normal activities with fewer complications and less pain. EBV therapy is a minimally invasive procedure and provides enormous benefits including improved lung function, and reduces less short of breath without taking the risk and recovering the traditional surgical treatment.On the basis of the End users, the market is segmented into Hospitals, Homecare, Speciality centres and others. The hospital segment is expected to lead the market with a significant CAGR during the forecast period. The increasing prevalence of chronic cough has pushed patients to enter hospitals for the treatment of it. A more advanced diagnosis process, medications and treatments are available in hospitals. In hospitals, the more effective drugs are provided with their levels of the cough and for the high level of the chronic cough, doctors offer the diagnosis process to find out the better solution of the chronic cough.

Chronic Cough Market Regional Insights

North America held the Chronic Cough Market in 2022 with the largest market share and is expected to continue its dominance over the forecast period. The regional market is driven by the increasing prevalence of chronic cough, technological developments in the pharmaceuticals and biopharmaceutical industry to innovate more effective drugs for chronic cough, the increasing geriatric population and growing consumer preference towards fast food.

The United States is expected to grow significantly for the chronic cough market during the forecast period. In the United States, the prevalence of chronic cough is approximately 5 % of adults. The development of Gefapixant in the US is an investigational and selective P2X3 receptor antagonist for the treatment of chronic cough. The inhibition of the binding of the Adenosine triphosphate (ATP) to P2X3 receptors reduces chronic cough.

Asia Pacific is expected to have a significant CAGR for the Chronic Cough Market over the forecast period. The increasing incidences of chronic cough, the presence of the key players, the development of drugs for the treatment of chronic cough and growing government initiatives for the improvement of the healthcare infrastructure. India has the major market for chronic cough and leads the regional market. The prevalence of chronic cough was reported to be 2.7 % among women in rural areas according to the definition of chronic bronchitis. The increasing number of smokers and the rapidly growing population are also factors that help to drive the growth of the market.

Competitive Landscape

The Competitive Landscape of the Chronic Cough market covers a number of key companies. It also focuses on the power of the company’s competitive rivals, potential, new market entrants, customers, suppliers and substitute products that drive the profitability of the companies in the Chronic Cough industry. The global Chronic Cough markets include various market players at the country, regional and global levels. The global markets include several market players at country, regional and global levels. These key players are adopting several strategies including investments, partnerships, mergers and acquisitions and joint ventures. The many companies investing in the development of new drugs for the treatment of chronic cough.

NeRRe: NeRRe developing orvepitant, a neurokinin (NK)-1 receptor antagonist used for the daily treatment of cough hypersensitivity disorders. The NeRRe has been continuing for the development of the chronic cough caused by the terminal and rare lung disease pulmonaryic pulmonary fibrosis (IPF). This is the class of antiemetic drugs which possess unique antidepressant, anxiolytic, and antiemetic properties. It is the most effective receptor to treat postsurgical nausea and vomiting which are the causes of chronic cough.

Chronic Cough Market Scope: Inquire before buying

Chronic Cough Market
Report Coverage	Details
Base Year:	2022	Forecast Period:	2023-2029
Historical Data:	2018 to 2022	Market Size in 2022:	US $ 6.59 Bn.
Forecast Period 2023 to 2029 CAGR:	8.2%	Market Size in 2029:	US $ 11.44 Bn.
Segments Covered:	by Drug Class	Antihistamines Corticosteroids Decongestants Combination Drugs Antibiotics Acid Blockers Other
	by Diagnosis	End bronchial Valve (EBV) Therapy Bronchoscopy Chest Radiography CT scan Echocardiogram (Echo) Others
	by Route of Administration	Oral Injections Inhalation Others
	by End-Users	Hospitals Homecare Specialty Centres Others
	by Distribution Channel	Hospital Pharmacy Online Pharmacy Retail Pharmacy

Chronic Cough Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and the Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and the Rest of APAC)
South America (Brazil, Argentina Rest of South America)
Middle East & Africa (South Africa, GCC, Egypt, Nigeria and the Rest of ME&A)

Chronic Cough Key Players

1. Cipla Inc.
2. Reckitt Benckiser Group plc.
3. Hikma Pharmaceuticals Plc
4. NeRRe Therapeutics (U.K.)
5. Merck
6. Novartis
7. Bellus Health
8. Teva Pharmaceutical Industries Ltd.
9. Sun Pharmaceutical Industries Ltd. (India)
10. Aurobindo Pharma (India)
11. Bristol-Myers Squibb Company (U.S.)
12. Biocon (India)
13. Shionogi
14. Bayer
15. Micro Labs Ltd
16. Apotex Inc.
17. Amneal Pharmaceuticals LLC
18. Aurobindo Pharma
19. Glenmark Pharmaceuticals Ltd

Frequently Asked Questions:

1] What is the growth rate of the Global Chronic Cough Market?
Ans. The Global Chronic Cough Market is growing at a significant rate of 8.2 % during the forecast period.

2] Which region is expected to dominate the Global Chronic Cough Market?
Ans. North America is expected to dominate the Chronic Cough Market during the forecast period.

3] What is the expected Global Chronic Cough Market size by 2029?
Ans. The Chronic Cough Market size is expected to reach USD 11.44 Bn by 2029.

4] Which are the top players in the Global Chronic Cough Market?
Ans. The major top players in the Global Chronic Cough Market are Cipla Inc. , Reckitt Benckiser Group plc., Hikma Pharmaceuticals Plc, NeRRe Therapeutics (U.K.), Merck, Novartis, Bellus Health, Teva Pharmaceutical Industries Ltd. And others.

5] What are the factors driving the Global Chronic Cough Market growth?
Ans. The increasing prevalence of chronic cough and developments of the drugs treating chronic cough are expected to drive market growth during the forecast period.

1. Chronic Cough Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Chronic Cough Market: Dynamics 2.1. Chronic Cough Market Trends by Region 2.1.1. North America Chronic Cough Market Trends 2.1.2. Europe Chronic Cough Market Trends 2.1.3. Asia Pacific Chronic Cough Market Trends 2.1.4. Middle East and Africa Chronic Cough Market Trends 2.1.5. South America Chronic Cough Market Trends 2.2. Chronic Cough Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America Chronic Cough Market Drivers 2.2.1.2. North America Chronic Cough Market Restraints 2.2.1.3. North America Chronic Cough Market Opportunities 2.2.1.4. North America Chronic Cough Market Challenges 2.2.2. Europe 2.2.2.1. Europe Chronic Cough Market Drivers 2.2.2.2. Europe Chronic Cough Market Restraints 2.2.2.3. Europe Chronic Cough Market Opportunities 2.2.2.4. Europe Chronic Cough Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific Chronic Cough Market Drivers 2.2.3.2. Asia Pacific Chronic Cough Market Restraints 2.2.3.3. Asia Pacific Chronic Cough Market Opportunities 2.2.3.4. Asia Pacific Chronic Cough Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa Chronic Cough Market Drivers 2.2.4.2. Middle East and Africa Chronic Cough Market Restraints 2.2.4.3. Middle East and Africa Chronic Cough Market Opportunities 2.2.4.4. Middle East and Africa Chronic Cough Market Challenges 2.2.5. South America 2.2.5.1. South America Chronic Cough Market Drivers 2.2.5.2. South America Chronic Cough Market Restraints 2.2.5.3. South America Chronic Cough Market Opportunities 2.2.5.4. South America Chronic Cough Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technology Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Key Opinion Leader Analysis For Chronic Cough Industry 2.8. Analysis of Government Schemes and Initiatives For Chronic Cough Industry 2.9. Chronic Cough Market Trade Analysis 2.10. The Global Pandemic Impact on Chronic Cough Market 3. Chronic Cough Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2022-2029 3.1. Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 3.1.1. Antihistamines 3.1.2. Corticosteroids 3.1.3. Decongestants 3.1.4. Combination Drugs 3.1.5. Antibiotics 3.1.6. Acid Blockers 3.1.7. Other 3.2. Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 3.2.1. End bronchial Valve (EBV) Therapy 3.2.2. Bronchoscopy 3.2.3. Chest Radiography 3.2.4. CT scan 3.2.5. Echocardiogram (Echo) 3.2.6. Others 3.3. Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 3.3.1. Oral 3.3.2. Injections 3.3.3. Inhalation 3.3.4. Others 3.4. Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 3.4.1. Hospitals 3.4.2. Homecare 3.4.3. Specialty Centres 3.4.4. Others 3.5. Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 3.5.1. Hospital Pharmacy 3.5.2. Online Pharmacy 3.5.3. Retail Pharmacy 3.6. Chronic Cough Market Size and Forecast, by Region (2022-2029) 3.6.1. North America 3.6.2. Europe 3.6.3. Asia Pacific 3.6.4. Middle East and Africa 3.6.5. South America 4. North America Chronic Cough Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 4.1. North America Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 4.1.1. Antihistamines 4.1.2. Corticosteroids 4.1.3. Decongestants 4.1.4. Combination Drugs 4.1.5. Antibiotics 4.1.6. Acid Blockers 4.1.7. Other 4.2. North America Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 4.2.1. End bronchial Valve (EBV) Therapy 4.2.2. Bronchoscopy 4.2.3. Chest Radiography 4.2.4. CT scan 4.2.5. Echocardiogram (Echo) 4.2.6. Others 4.3. North America Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 4.3.1. Oral 4.3.2. Injections 4.3.3. Inhalation 4.3.4. Others 4.4. North America Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 4.4.1. Hospitals 4.4.2. Homecare 4.4.3. Specialty Centres 4.4.4. Others 4.5. North America Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 4.5.1. Hospital Pharmacy 4.5.2. Online Pharmacy 4.5.3. Retail Pharmacy 4.7. North America Chronic Cough Market Size and Forecast, by Country (2022-2029) 4.6.1. United States 4.6.1.1. United States Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 4.6.1.1.1. Antihistamines 4.6.1.1.2. Corticosteroids 4.6.1.1.3. Decongestants 4.6.1.1.4. Combination Drugs 4.6.1.1.5. Antibiotics 4.6.1.1.6. Acid Blockers 4.6.1.1.7. Other 4.6.1.2. United States Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 4.6.1.2.1. End bronchial Valve (EBV) Therapy 4.6.1.2.2. Bronchoscopy 4.6.1.2.3. Chest Radiography 4.6.1.2.4. CT scan 4.6.1.2.5. Echocardiogram (Echo) 4.6.1.2.6. Others 4.6.1.3. United States Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 4.6.1.3.1. Oral 4.6.1.3.2. Injections 4.6.1.3.3. Inhalation 4.6.1.3.4. Others 4.6.1.4. United States Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 4.6.1.4.1. Hospitals 4.6.1.4.2. Homecare 4.6.1.4.3. Specialty Centres 4.6.1.4.4. Others 4.6.1.5. United States Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 4.6.1.5.1. Hospital Pharmacy 4.6.1.5.2. Online Pharmacy 4.6.1.5.3. Retail Pharmacy 4.6.2. Canada 4.6.2.1. Canada Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 4.6.2.1.1. Antihistamines 4.6.2.1.2. Corticosteroids 4.6.2.1.3. Decongestants 4.6.2.1.4. Combination Drugs 4.6.2.1.5. Antibiotics 4.6.2.1.6. Acid Blockers 4.6.2.1.7. Other 4.6.2.2. Canada Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 4.6.2.2.1. End bronchial Valve (EBV) Therapy 4.6.2.2.2. Bronchoscopy 4.6.2.2.3. Chest Radiography 4.6.2.2.4. CT scan 4.6.2.2.5. Echocardiogram (Echo) 4.6.2.2.6. Others 4.6.2.3. Canada Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 4.6.2.3.1. Oral 4.6.2.3.2. Injections 4.6.2.3.3. Inhalation 4.6.2.3.4. Others 4.6.2.4. Canada Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 4.6.2.4.1. Hospitals 4.6.2.4.2. Homecare 4.6.2.4.3. Specialty Centres 4.6.2.4.4. Others 4.6.2.5. Canada Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 4.6.2.5.1. Hospital Pharmacy 4.6.2.5.2. Online Pharmacy 4.6.2.5.3. Retail Pharmacy 4.6.3. Mexico 4.6.3.1. Mexico Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 4.6.3.1.1. Antihistamines 4.6.3.1.2. Corticosteroids 4.6.3.1.3. Decongestants 4.6.3.1.4. Combination Drugs 4.6.3.1.5. Antibiotics 4.6.3.1.6. Acid Blockers 4.6.3.1.7. Other 4.6.3.2. Mexico Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 4.6.3.2.1. End bronchial Valve (EBV) Therapy 4.6.3.2.2. Bronchoscopy 4.6.3.2.3. Chest Radiography 4.6.3.2.4. CT scan 4.6.3.2.5. Echocardiogram (Echo) 4.6.3.2.6. Others 4.6.3.3. Mexico Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 4.6.3.3.1. Oral 4.6.3.3.2. Injections 4.6.3.3.3. Inhalation 4.6.3.3.4. Others 4.6.3.4. Mexico Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 4.6.3.4.1. Hospitals 4.6.3.4.2. Homecare 4.6.3.4.3. Specialty Centres 4.6.3.4.4. Others 4.6.3.5. Mexico Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 4.6.3.5.1. Hospital Pharmacy 4.6.3.5.2. Online Pharmacy 4.6.3.5.3. Retail Pharmacy 5. Europe Chronic Cough Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 5.1. Europe Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 5.2. Europe Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 5.3. Europe Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 5.4. Europe Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 5.5. Europe Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 5.6. Europe Chronic Cough Market Size and Forecast, by Country (2022-2029) 5.6.1. United Kingdom 5.6.1.1. United Kingdom Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 5.6.1.2. United Kingdom Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 5.6.1.3. United Kingdom Chronic Cough Market Size and Forecast, by Route of Administration(2022-2029) 5.6.1.4. United Kingdom Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 5.6.1.5. United Kingdom Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 5.6.2. France 5.6.2.1. France Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 5.6.2.2. France Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 5.6.2.3. France Chronic Cough Market Size and Forecast, by Route of Administration(2022-2029) 5.6.2.4. France Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 5.6.2.5. France Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 5.6.3. Germany 5.6.3.1. Germany Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 5.6.3.2. Germany Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 5.6.3.3. Germany Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 5.6.3.4. Germany Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 5.6.3.5. Germany Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 5.6.4. Italy 5.6.4.1. Italy Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 5.6.4.2. Italy Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 5.6.4.3. Italy Chronic Cough Market Size and Forecast, by Route of Administration(2022-2029) 5.6.4.4. Italy Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 5.6.4.5. Italy Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 5.6.5. Spain 5.6.5.1. Spain Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 5.6.5.2. Spain Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 5.6.5.3. Spain Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 5.6.5.4. Spain Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 5.6.5.5. Spain Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 5.6.6. Sweden 5.6.6.1. Sweden Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 5.6.6.2. Sweden Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 5.6.6.3. Sweden Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 5.6.6.4. Sweden Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 5.6.6.5. Sweden Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 5.6.7. Austria 5.6.7.1. Austria Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 5.6.7.2. Austria Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 5.6.7.3. Austria Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 5.6.7.4. Austria Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 5.6.7.5. Austria Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 5.6.8. Rest of Europe 5.6.8.1. Rest of Europe Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 5.6.8.2. Rest of Europe Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 5.6.8.3. Rest of Europe Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 5.6.8.4. Rest of Europe Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 5.6.8.5. Rest of Europe Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 6. Asia Pacific Chronic Cough Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 6.1. Asia Pacific Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 6.2. Asia Pacific Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 6.3. Asia Pacific Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 6.4. Asia Pacific Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 6.5. Asia Pacific Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 6.6. Asia Pacific Chronic Cough Market Size and Forecast, by Country (2022-2029) 6.6.1. China 6.6.1.1. China Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 6.6.1.2. China Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 6.6.1.3. China Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 6.6.1.4. China Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 6.6.1.5. China Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 6.6.2. S Korea 6.6.2.1. S Korea Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 6.6.2.2. S Korea Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 6.6.2.3. S Korea Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 6.6.2.4. S Korea Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 6.6.2.5. S Korea Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 6.6.3. Japan 6.6.3.1. Japan Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 6.6.3.2. Japan Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 6.6.3.3. Japan Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 6.6.3.4. Japan Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 6.6.3.5. Japan Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 6.6.4. India 6.6.4.1. India Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 6.6.4.2. India Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 6.6.4.3. India Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 6.6.4.4. India Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 6.6.4.5. India Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 6.6.5. Australia 6.6.5.1. Australia Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 6.6.5.2. Australia Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 6.6.5.3. Australia Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 6.6.5.4. Australia Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 6.6.5.5. Australia Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 6.6.6. Indonesia 6.6.6.1. Indonesia Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 6.6.6.2. Indonesia Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 6.6.6.3. Indonesia Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 6.6.6.4. Indonesia Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 6.6.6.5. Indonesia Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 6.6.7. Malaysia 6.6.7.1. Malaysia Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 6.6.7.2. Malaysia Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 6.6.7.3. Malaysia Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 6.6.7.4. Malaysia Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 6.6.7.5. Malaysia Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 6.6.8. Vietnam 6.6.8.1. Vietnam Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 6.6.8.2. Vietnam Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 6.6.8.3. Vietnam Chronic Cough Market Size and Forecast, by Route of Administration(2022-2029) 6.6.8.4. Vietnam Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 6.6.8.5. Vietnam Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 6.6.9. Taiwan 6.6.9.1. Taiwan Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 6.6.9.2. Taiwan Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 6.6.9.3. Taiwan Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 6.6.9.4. Taiwan Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 6.6.9.5. Taiwan Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 6.6.10. Rest of Asia Pacific 6.6.10.1. Rest of Asia Pacific Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 6.6.10.2. Rest of Asia Pacific Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 6.6.10.3. Rest of Asia Pacific Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 6.6.10.4. Rest of Asia Pacific Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 6.6.10.5. Rest of Asia Pacific Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 7. Middle East and Africa Chronic Cough Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 7.1. Middle East and Africa Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 7.2. Middle East and Africa Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 7.3. Middle East and Africa Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 7.4. Middle East and Africa Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 7.5. Middle East and Africa Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 7.6. Middle East and Africa Chronic Cough Market Size and Forecast, by Country (2022-2029) 7.6.1. South Africa 7.6.1.1. South Africa Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 7.6.1.2. South Africa Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 7.6.1.3. South Africa Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 7.6.1.4. South Africa Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 7.6.1.5. South Africa Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 7.6.2. GCC 7.6.2.1. GCC Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 7.6.2.2. GCC Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 7.6.2.3. GCC Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 7.6.2.4. GCC Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 7.6.2.5. GCC Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 7.6.3. Nigeria 7.6.3.1. Nigeria Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 7.6.3.2. Nigeria Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 7.6.3.3. Nigeria Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 7.6.3.4. Nigeria Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 7.6.3.5. Nigeria Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 7.6.4. Rest of ME&A 7.6.4.1. Rest of ME&A Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 7.6.4.2. Rest of ME&A Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 7.6.4.3. Rest of ME&A Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 7.6.4.4. Rest of ME&A Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 7.6.4.5. Rest of ME&A Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 8. South America Chronic Cough Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 8.1. South America Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 8.2. South America Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 8.3. South America Chronic Cough Market Size and Forecast, by Route of Administration(2022-2029) 8.4. South America Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 8.5. South America Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 8.6. South America Chronic Cough Market Size and Forecast, by Country (2022-2029) 8.7.1. Brazil 8.6.1.1. Brazil Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 8.6.1.2. Brazil Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 8.6.1.3. Brazil Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 8.6.1.4. Brazil Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 8.6.1.5. Brazil Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 8.7.2. Argentina 8.6.2.1. Argentina Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 8.6.2.2. Argentina Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 8.6.2.3. Argentina Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 8.6.2.4. Argentina Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 8.6.2.5. Argentina Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 8.7.3. Rest Of South America 8.6.3.1. Rest Of South America Chronic Cough Market Size and Forecast, by Drug Class (2022-2029) 8.6.3.2. Rest Of South America Chronic Cough Market Size and Forecast, by Diagnosis (2022-2029) 8.6.3.3. Rest Of South America Chronic Cough Market Size and Forecast, by Route of Administration (2022-2029) 8.6.3.4. Rest Of South America Chronic Cough Market Size and Forecast, by End-Users (2022-2029) 8.6.3.5. Rest Of South America Chronic Cough Market Size and Forecast, by Distribution Channel (2022-2029) 9. Global Chronic Cough Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Business Segment 9.3.3. End-user Segment 9.3.4. Revenue (2022) 9.3.5. Company Locations 9.4. Leading Chronic Cough Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. Cipla Inc. 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Reckitt Benckiser Group plc. 10.3. Hikma Pharmaceuticals Plc 10.4. NeRRe Therapeutics (U.K.) 10.5. Merck 10.6. Novartis 10.7. Bellus Health 10.8. Teva Pharmaceutical Industries Ltd. 10.9. Sun Pharmaceutical Industries Ltd. (India) 10.10. Aurobindo Pharma (India) 10.11. Bristol-Myers Squibb Company (U.S.) 10.12. Biocon (India) 10.13. Shionogi 10.14. Bayer 10.15. Micro Labs Ltd 10.16. Apotex Inc. 10.17. Amneal Pharmaceuticals LLC 10.18. Aurobindo Pharma 10.19. Glenmark Pharmaceuticals Ltd 11. Key Findings 12. Industry Recommendations 13. Chronic Cough Market: Research Methodology 14. Terms and Glossary

Chronic Cough Market

Choose License Type